View Exam | PowerPak

1. What percentage of patients living with HIV in the United States are coinfected with HCV?

A. 1% B. 5% C. 25% D. 50%

2. Which of the following explains the reason for high rates of coinfection of HIV and HCV?

A. Both viruses can be transmitted via blood-blood contact B. Both viruses can be transmitted via aerosolized respiratory droplets C. Both viruses can be transmitted via contact with an infected surface D. Both viruses can form spores that live on environmental surfaces

3. The most common HCV genotype in the United States is which of the following:

A. Genotype 1 B. Genotype 2 C. Genotype 4 D. Genotype 6

4. According to the most recent CDC guidance, which of the following patients should be screened for HIV infection at least annually?

A. 22-year-old single woman who had a negative HIV screening test 6 months ago and has no risk factors for HIV during the past year B. 43-year-old man who is an injection drug user C. 68-year-old married woman in a monogamous relationship with her husband of 40 years D. 38-year-old man who has sex with men, had a negative HIV screening test 1 year ago, and has not been sexually active during the past year

5. Which of the following is a goal of antiretroviral therapy in patients living with HIV?

A. Prevent HIV transmission B. Restore and preserve immunologic function C. Maximally and durably suppress plasma HIV viral load D. All of the above

6. A sustained virologic response in a patient treated for HCV is defined as:

A. The continued absence of detectable HCV RNA at least 4 weeks following completion of HCV therapy B. The continued absence of detectable HCV RNA at least 8 weeks following completion of HCV therapy C. The continued absence of detectable HCV RNA at least 12 weeks following completion of HCV therapy D. None of the above

7. Which of the following antiretroviral therapy choices is a recommended initial regimen for most antiretroviral-naive HIV-infected patients?

A. Dolutegravir + tenofovir disoproxil fumarate/emtricitabine B. Efavirenz/tenofovir/emtricitabine C. Abacavir/lamivudine/zidovudine D. Tipranavir + lamivudine/zidovudine

8. Which of the following HCV choices represents a recommended regimen for a noncirrhotic, treatment-naive HCV-infected patient with genotype 1a?

A. Daily glecaprevir (300 mg)/pibrentasvir (120 mg) for 8 weeks B. Daily ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks C. Daily sofosbuvir (400 mg)/velpatasvir (100 mg) for 12 weeks D. All of the above

9. Which of the following is the most appropriate dose of daclatasvir in a patient who is concomitantly being placed on an efavirenz-containing HIV regimen?

A. Daclatasvir 60 mg daily B. Daclatasvir 90 mg daily C. Daclatasvir 30 mg daily D. Daclatasvir 10 mg daily

10. Combining which of the following DAAs with tenofovir disoproxil fumarate (TDF) can result in increased TDF levels, requiring close monitoring for tenofovir-related toxicity?

A. Ledipasvir/sofosbuvir B. Elbasvir/grazoprevir C. Glecaprevir/pibrentasvir D. Ombitasvir/paritaprevir/ritonavir + dasabuvir